News

The FDA has requested supplemental validation information and comparability data for the tumor-infiltrating therapy.

Review top news and interview highlights from the week ending November 18, 2022.

The director of the CCU/ICU at Saint John’s Health Center discussed unmet respiratory treatment needs in the beginning of the COVID-19 pandemic.

Editas has paused enrollment in the BRILLIANCE trial after efficacy was only seen in a very small subset of patients.

CAN-2409 transduces tumor cells with the thymidine kinase gene, sensitizes these cells to valacyclovir, and stimulates patients’ immune response.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Updated data from a first-in-human trial were presented at the SITC 2022 meeting.

The chief of research and immunotherapy at Cedars-Sinai The Angeles Clinic and Research Institute discussed updated data from the phase 2 C-144-01 study of the lifileucel TIL therapy.

4D Molecular Therapeutics plans to initiate enrollment in the phase 2 randomized portion of the study in the first quarter of 2023.

The first 3 patients dosed have been attack-free for up to 10.5 months.

The Genomics and Epigenetic Guided Safe Harbor mapper will aid in the future design of gene-editing therapies.

A2B530 and A2B694 target CEA and MSLN cells that have HLA loss of heterozygosity.

Review top news and interview highlights from the week ending November 11, 2022.

Data from the COBALT-RCC study in renal cell carcinoma were presented at SITC 2022.

The CRIPSR-edited neoantigen-specific T cell therapy demonstrated safety and feasibility in the first-in-human PACT-0101 study presented at SITC 2022.

Further analysis will be performed to elucidate which characteristics correlate with optimal cell therapy behavior.

The FDA action follows a slew of recent cell and gene therapy updates in the field of amyotrophic lateral sclerosis.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Several of the first cohort patients have had their Cell Pouch implants for over 3 years and no patients have elected to have their implants removed.

The director of translational research in myeloma at the Tisch Cancer Institute discussed the relevance of the new research as more CAR T therapies come to market.

Recent communication with the FDA suggests that the agency's decision might be delayed past Q1 2023.

A final evidence report suggests a $1.9 million cap for val-rox and a $2.9 million cap for EtranaDez.

Preclinical research in an OTOF-knockout mouse model demonstrated reversal of deafness.

No treatment-related adverse events have been reported and Verve expects a letter detailing the hold within 30 days.

The trial was launched through a partnership between Cure Rare Disease and UMass Chan Medical School.

The assistant professor of Hematologic Oncology and Blood Disorders at Atrium Health discussed integrating CAR T therapy into treatment paradigms.

The platform is capable of producing lentiviral vectors for preclinical, clinical, and commercial scales with high titers ranging from 1x10^8 TU/ml to 1x10^9 TU/ml.

The chair of gynecologic oncology at Moffitt Cancer Center gave an overview of a phase 1 trial being conducted at Moffitt Cancer Center.